Rituximab and infliximab desensitization with anti-IgE monoclonal antibody omalizumab as adjuvant therapy: a case series.
The journal of allergy and clinical immunology. In practice（2022）
摘要
IgE-mediated mechanisms can be involved in HSR to biologicals. Omalizumab allows safe and successful drug administration in DD protocols previously complicated by breakthrough reactions.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要